Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Plaque Psoriasis
Open-data reference.
46 US clinical trials · 10 currently recruiting
Active & Recent Trials
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
NCT07116967
Psorcast Mobile Study
Sage Bionetworks
NCT05621369
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb
NCT06979453
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Oruka Therapeutics
NCT07290569
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Takeda
NCT07250802
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
Ascletis Pharma (China) Co., Limited
NCT07024602
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics
NCT07449702
Bimekizumab in Plaque Psoriasis
Icahn School of Medicine at Mount Sinai
NCT06336343
Guselkumab Immunogenetics
University of California, San Francis
NCT04645355
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
Wright State University
NCT04036188
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
Takeda
NCT06550076
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Alumis
NCT06846541
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Alumis
NCT06586112
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
Alumis
NCT06588738
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Janssen Research & Development
NCT06143878
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Janssen Research & Development
NCT06934226
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
Janssen Research & Development
NCT06220604
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Janssen Research & Development
NCT06095115
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Takeda
NCT06973291
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
Janssen Research & Development
NCT06095102
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
Alumis
NCT05739435
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Oruka Therapeutics
NCT07090330
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Organon and
NCT05172726
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Amgen
NCT06088199
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
AbbVie (prior sponsor, Abbott)
NCT00570986
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
Arcutis Biotherapeutics
NCT03638258
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
UCB Biopharma S.P.R.L.
NCT02326298
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
NCT05896527
A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
UCB Biopharma S.P.R.L.
NCT02326272
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
Therapeutics
NCT01882647
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)
Therapeutics
NCT01871402
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
Bausch Health Americas
NCT02514577
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Bausch Health Americas
NCT02462070
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
Akros Pharma
NCT03832738
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis
Therapeutics
NCT02367911
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
Sun Pharmaceutical Industries
NCT02618759
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
Pfizer
NCT04664153
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
Pfizer
NCT02310750
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
Hangzhou Highlightll Pharmaceutical Co.
NCT05772520
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
Primus Pharmaceuticals
NCT02749799
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
Galderma R&D
NCT01893567
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
Sun Pharmaceutical Industries
NCT02601469
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
Therapeutics
NCT01698333
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
Mayne Pharma International Pty
NCT03992261
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
Organon and
NCT04042103
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
Wake Forest University
NCT01707043
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 3 |
| Phase 2 | 12 |
| Phase 3 | 24 |
| Phase 4 | 6 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Plaque Psoriasis Trial Landscape
ClinicalTrials.gov lists 46 US studies indexed under Plaque Psoriasis, and 10 of those are currently open to recruitment — roughly 22% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Plaque Psoriasis shows 30 late-stage studies (Phase 3 and Phase 4 combined) alongside 15 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Plaque Psoriasis is led by Janssen Research & Development with 5 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 46 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Plaque Psoriasis?
PlainTrial tracks 46 US clinical trials for Plaque Psoriasis, of which 10 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Plaque Psoriasis?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.